Works matching IS 10837159 AND DT 2020 AND VI 25 AND IP 1

Results: 36
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities.

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e186, doi. 10.1634/theoncologist.2019-0221
    By:
    • Kim, Young Saing;
    • Ji, Jun Ho;
    • Oh, Sung Yong;
    • Lee, Suee;
    • Huh, Seok Jae;
    • Lee, Ji Hyun;
    • Song, Ki‐Hoon;
    • Son, Choon Hee;
    • Roh, Mee Sook;
    • Lee, Gyeong Won;
    • Lee, Jeeyun;
    • Kim, Seung Tae;
    • Kim, Chan Kyu;
    • Jang, Joung Soon;
    • Hwang, In Gyu;
    • Ahn, Hee Kyung;
    • Park, Lee Chun;
    • Oh, So Yeon;
    • Kim, Seong‐Geun;
    • Lee, Sang‐Cheol
    Publication type:
    Article
    17
    18
    19

    Regorafenib in Combination with First‐Line Chemotherapy for Metastatic Esophagogastric Cancer.

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e68, doi. 10.1634/theoncologist.2019-0492
    By:
    • Moy, Ryan H.;
    • Dos Santos Fernandes, Gustavo;
    • Jonsson, Philip;
    • Chou, Joanne F.;
    • Basunia, Azfar;
    • Ku, Geoffrey Y.;
    • Chalasani, Sree B.;
    • Boyar, Michelle S.;
    • Goldberg, Zoe;
    • Desai, Avni M.;
    • Gabler, Amelia;
    • Berger, Michael F.;
    • Tang, Laura H.;
    • Hechtman, Jaclyn F.;
    • Kelsen, David P.;
    • Schattner, Mark;
    • Ilson, David H.;
    • Solit, David B.;
    • Taylor, Barry S.;
    • Schultz, Nikolaus
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e160, doi. 10.1634/theoncologist.2019-0297
    By:
    • Bardia, Aditya;
    • Gounder, Mrinal;
    • Rodon, Jordi;
    • Janku, Filip;
    • Lolkema, Martijn P.;
    • Stephenson, Joe J.;
    • Bedard, Philippe L.;
    • Schuler, Martin;
    • Sessa, Cristiana;
    • LoRusso, Patricia;
    • Thomas, Michael;
    • Maacke, Heiko;
    • Evans, Helen;
    • Sun, Yongjian;
    • Tan, Daniel S.W.
    Publication type:
    Article
    30
    31
    32

    The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e39, doi. 10.1634/theoncologist.2018-0528
    By:
    • Disel, Umut;
    • Madison, Russell;
    • Abhishek, Kumar;
    • Chung, Jon H.;
    • Trabucco, Sally E.;
    • Matos, Asli O.;
    • Frampton, Garrett M.;
    • Albacker, Lee A.;
    • Reddy, Venkataprasanth;
    • Karadurmus, Nuri;
    • Benson, Adam;
    • Webster, Jennifer;
    • Paydas, Semra;
    • Cabanillas, Ruben;
    • Nangia, Chaitali;
    • Ozturk, M.A.;
    • Millis, Sherri Z.;
    • Pal, Sumanta K.;
    • Wilky, Breelyn;
    • Sokol, Ethan S.
    Publication type:
    Article
    33
    34

    Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5‐Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG‐ACRIN Cancer Research Group (E2205)

    Published in:
    Oncologist, 2020, v. 25, n. 1, p. e53, doi. 10.1634/theoncologist.2018-0750
    By:
    • Gibson, Michael K.;
    • Catalano, Paul;
    • Kleinberg, Lawrence R.;
    • Staley, Charles A.;
    • Montgomery, Elizabeth A.;
    • Jimeno, Antonio;
    • Song, Wei (Frank);
    • Mulcahy, Mary F.;
    • Leichman, Lawrence P.;
    • Benson, Al B.
    Publication type:
    Article
    35
    36